The biologics market comprises companies manufacturing biological products that are derived from genetically modified proteins and human genes. Biologics products include a wide range of recombinant therapeutic proteins, vaccines, and monoclonal antibodies. These products are isolated from natural sources such as human, animal, and microorganisms by biotechnological methods and other cutting-edge technologies.
This report also includes market information on the monoclonal antibody therapeutics market, anti-infective market, cardiovascular market, metabolic disorders market, and immunological disorders market.
The top five companies covered are Johnson & Johnson, F.Hoffmann-La Roche, Bristol-Myers Squibb, GlaxoSmithKline, and AbbVie. Johnson & Johnson was the largest competitor in the global biologics market in 2017.
The countries covered are India, China, Japan, Australia, UK, Germany, France, Italy, Spain, Russia, USA, and Brazil.
The global biologics market was valued at $221 billion in 2017. North America was the largest region in the biologics market in 2017, accounting for around 40% of the market. The USA was the largest country in 2017, accounting for less than 30% of the market share.
Biologics are being widely used to provide effective treatment for many complex diseases such as rheumatoid arthritis, psoriasis, Crohn’s disease that have limited treatment options. There has been a significant advance in the treatment of rheumatoid arthritis patients who do not respond to traditional disease-modifying anti-rheumatic drugs. The key biologics used for the treatment of rheumatoid arthritis include Abatacept (Orencia), Adalimumab (Humira), Anakinra (Kineret), Infliximab (Remicade), and Rituximab (Rituxan). Key biologics used to treat psoriasis include Adalimumab (Humira), Etanercept (Enbrel), Infliximab?(Remicade), Secukinumab (?Cosentyx). Cimzia (certolizumab pegol), Humira (adalimumab), and Remicade (infliximab), Tysabri (natalizumab) are biologics that are used to treat Crohn’s disease.
The Global Biologics Market is segmented into Monoclonal Antibodies, Therapeutic Proteins, Vaccines.
Monoclonal Antibodies Market Monoclonal antibodies (mAb) are cells derived by cell division from a single ancestral cell. Monoclonal antibodies target specific cell-surface receptors. These mAbs recognize and bind to antigens, a molecule that induces the immune system, in order to discriminate between specific epitopes (the part of an antigen that is recognized by the antibody) which provide protection against disease organisms.
Protein Therapeutics Market therapeutic proteins are proteins that are engineered in the laboratory for pharmaceutical use. Therapeutic proteins permit an individualized treatment approach by supporting a specifically targeted therapeutic process which compensates for the deficiency of an essential protein. These proteins are also referred to as recombinant proteins as they are produced by recombinant DNA technology. The market for protein drugs is analyzed broadly under the following types: peptide hormones, cytokines, therapeutic enzymes, and vaccines.
Vaccines Market vaccines are biological preparations that stimulate the immune system and prepares it to fight future infections caused by pathogens. They trigger the production of antibodies against pathogens or any foreign matter that enters the body. Vaccines can be administered orally, through injections or by aerosol. Vaccine doses are administered to both children (pediatric vaccines) and adults based on the schedule set for each vaccine. For adults, the vaccines are recommended based on age, health condition, prior vaccinations and occupation.